[ad_1] New study data also confirm STELARA's effectiveness® (Ustekinumab) in tumor necrosis factor (TNF) antagonist-naive patients or those who do not tolerate this Janssen Pharmaceuticals of Johnson & Johnson today announced new …
Read More »Janssen's STELARA® (ustekinumab) Shows Lasting Efficacy to Improve Clinical Remission Rates in Patients with Moderate to Severe Crohn's Disease over a Three-Year Period
